Jounce Therapeutics, Inc. (JNCE) financial statements (2021 and earlier)

Company profile

Business Address 780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments206169190236
Cash and cash equivalents147534824
Short-term investments59116142212
Receivables  018
Prepaid expense  22
Other current assets   0
Other undisclosed current assets55  
Total current assets:211174192256
Noncurrent Assets
Operating lease, right-of-use asset1518
Property, plant and equipment7111416
Long-term investments and receivables72622
Long-term investments72622
Other noncurrent assets4233
Total noncurrent assets:33322241
TOTAL ASSETS:244206214297
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14111011
Accounts payable2233
Accrued liabilities12978
Deferred revenue2 
Debt 3  
Deferred rent credit  0
Deferred revenue and credits51
Contract with customer, liability55
Other liabilities0000
Other undisclosed current liabilities3   
Total current liabilities:19146663
Noncurrent Liabilities
Long-term debt and lease obligation1417  
Operating lease, liability1417
Liabilities, other than long-term debt  4567
Deferred revenue and credits67
Contract with customer, liability43
Deferred rent credit  2
Other liabilities   0
Other undisclosed noncurrent liabilities(14)   
Total noncurrent liabilities:14174567
Total liabilities:3331110130
Stockholders' equity
Stockholders' equity attributable to parent211175104167
Common stock0000
Additional paid in capital362282268257
Accumulated other comprehensive income (loss)(0)0(0)(0)
Accumulated deficit(151)(107)(164)(90)
Total stockholders' equity:211175104167
TOTAL LIABILITIES AND EQUITY:244206214297

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenue, net72
Revenue from related parties6214865
Gross profit:621486572
Operating expenses(107)(95)(96)(91)
Operating income (loss):(45)53(31)(19)
Nonoperating income
(Other Nonoperating income)
1443
Income (loss) from continuing operations before income taxes:(44)57(27)(16)
Income tax expense(0)(0)(0)(0)
Net income (loss) attributable to parent:(44)57(27)(16)
Other undisclosed net loss available to common stockholders, basic   (1)
Net income (loss) available to common stockholders, diluted:(44)57(27)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(44)57(27)(16)
Comprehensive income (loss):(44)57(27)(16)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000
Comprehensive income (loss), net of tax, attributable to parent:(44)57(27)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: